指南与共识血管炎

2021年美国风湿病学会/血管炎基金会抗中性粒细胞胞质抗体相关血管炎管理指南

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2021-07-08

该指南由美国风湿病学会与血管炎基金会制定,针对GPA、MPA和EGPA的管理提出循证推荐。方法采用PICO格式构建临床问题、系统文献评价和GRADE分级,推荐需≥70%投票共识。共形成GPA/MPA 26条推荐和5条未分级立场声明,EGPA 15条推荐和5条未分级立场声明。

要点

  • 推荐利妥昔单抗用于重症GPA和MPA的诱导缓解及维持治疗。
  • 推荐美泊利单抗用于非重症EGPA。
  • 所有推荐均为条件性推荐,部分因缺乏多个随机对照试验和/或低质量证据。

核心结论

  • 该指南为GPA、MPA和EGPA的诱导缓解、维持治疗及辅助治疗策略提供推荐。
  • 所有推荐均为条件性推荐,部分因缺乏多个随机对照试验和/或低质量证据。

研究设计与样本

  • 指南针对GPA/MPA构建47个PICO问题、EGPA构建34个PICO问题,每个问题行系统文献评价。
  • 采用GRADE方法评估证据质量并形成推荐,每条推荐需投票面板≥70%共识。

主要发现

  • GPA/MPA部分形成26条推荐和5条未分级立场声明。
  • EGPA部分形成15条推荐和5条未分级立场声明。

关键数值与推荐

  • 推荐利妥昔单抗用于重症GPA和MPA的诱导缓解和维持治疗。
  • 推荐美泊利单抗用于非重症EGPA。
  • 所有推荐均为条件性推荐,部分因缺乏多个随机对照试验和/或低质量证据。

临床怎么用

  • 临床医生可参照该指南对GPA、MPA和EGPA进行诱导缓解、维持治疗及辅助治疗决策。
  • 需注意所有推荐均为条件性推荐,应结合证据质量和患者具体情况应用。

局限性

  • 部分推荐缺乏多个随机对照试验和/或低质量证据支持,导致推荐均为条件性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021. PMID: 34235880. doi:10.1002/acr.24634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。